Shanghai Henlius Biotech, Inc. (the “Company,” Stock Code: 2696) has released a proxy form for its 2025 fourth extraordinary general meeting (EGM), scheduled for 31 December 2025 at 9:00 a.m. The EGM will take place in the Conference Room, 10th Floor, B8 Building, No. 188 Yizhou Road, Xuhui District, Shanghai, People’s Republic of China.

Key business on the agenda includes consideration and potential approval of a Distribution Framework Agreement dated 3 December 2025 between the Company and Sinopharm Group Co. Ltd.* (國藥控股股份有限公司). The meeting will also review the corresponding annual caps for the proposed arrangement. Shareholders or their proxies who plan to attend must complete and submit the proxy form within the required deadline outlined in the announcement.

According to the proxy instruction, shareholders can appoint one or more representatives to vote on their behalf. The form specifies the necessary procedures for lodging such appointments and emphasizes the requirement to adhere to the designated timeline. If the proposal is passed, any Director of the Company will be authorized to undertake actions needed to implement the newly approved agreement frameworks and related transactions.